GO
Loading...

Pharmaceuticals

More

  • Drug Stocks: Real Downers And At A Two-Year Low Tuesday, 5 Feb 2008 | 4:29 PM ET

    Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.

  • Boston Scientific And The "Struggling" Stents Tuesday, 5 Feb 2008 | 10:25 AM ET

    Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.

  • FDA At Level "Orange" Safety Warning? Monday, 4 Feb 2008 | 2:14 PM ET

    The Food and Drug Administration continues to get a lot of attention and scrutiny. In an editorial over the weekend "The New York Times" wrote, "The F.D.A. desperately needs an infusion of money and talent." Then, "USA Today" today is running a front-page article on something I recently blogged about and other reporters tackled a few weeks ago regarding the agency approving so few drugs last year.

  • Pfizer's Chantix Suffers Yet Another Blow From FDA Friday, 1 Feb 2008 | 4:53 PM ET

    Pfizer tried to get out in front of the psychiatric side-effect issues on its stop-smoking drug by adding information about behavioral changes, mood swings, thoughts of suicide, etc. to the label last month.

  • Medtronic Gets Approval for Drug-Coated Stent Friday, 1 Feb 2008 | 4:36 PM ET

    Medtronic on Friday received federal approval to sell its drug-coated stent, the first to hit the U.S. market since safety concerns sank their popularity two years ago.

  • WHO Reports Tamiflu-Resistant Flu in US, Canada Friday, 1 Feb 2008 | 11:07 AM ET

    The main flu virus circulating in the United States and Canada has shown "elevated resistance" to the antiviral drug Tamiflu, in line with findings in parts of Europe, the World Health Organisation (WHO) said on Friday.

  • Glaxo, Merck, SGP & Amgen: Readers Have a Lot to Say Friday, 1 Feb 2008 | 10:51 AM ET

    It's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.

  • Bristol-Myers' Disappearing Penny: Case Is Now Closed Thursday, 31 Jan 2008 | 2:42 PM ET

    I just got off the phone with the Chief Operating Officer of PR Newswire, Dave Armon, who says the discrepancy between the two Bristol-Myers Squibb earnings press releases I've been blogging about was due to an information technology glitch at PR Newswire.

  • Novo Nordisk Beats Expectations on Strong Sales  Thursday, 31 Jan 2008 | 12:44 PM ET

    Operating profit at Denmark's Novo Nordisk slipped 2 percent last year but still beat analysts' expectations due to strong sales growth in the US and China, company CEO Lars Rebien told "Worldwide Exchange" on Thursday.

  • AstraZeneca Earnings Fall, Cost Cuts to Help '08 Thursday, 31 Jan 2008 | 12:40 PM ET

    AstraZeneca gave a cautious outlook for the year ahead on Thursday after meeting analyst forecasts with a 3 percent fall in 2007 earnings, and said market conditions remained challenging.

  • This morning on "Squawk on the Street" I did a pharma earnings round-up report and I topped it by saying the sector could remain under pressure today because two major American drug companies--Bristol-Myers Squibb and Wyeth-- missed earnings expectations and lowered their 2008 guidance.

  • Bristol-Myers Narrows Loss, Cuts Forecast Thursday, 31 Jan 2008 | 11:06 AM ET

    Bristol-Myers Squibb Thursday reported a loss from continuing operations as special charges more than offset strong sales growth of its array of prescription drugs.

  • Medicis Says FDA Rejects Wrinkle Drug Reloxin Thursday, 31 Jan 2008 | 9:34 AM ET

    Medicis Pharmaceutical said on Thursday the U.S. Food and Drug Administration had decided that the company's Biologics License Application for the botulinum toxin type A, called Reloxin, in aesthetics was incomplete.

  • Sudden Death: Pfizer, Level 3, Sara Lee and More Wednesday, 30 Jan 2008 | 7:19 PM ET

    It's a booyah-free zone. There goes Swifty!Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Glaxo's Avandia Leak: Who Really Broke Embargo? Wednesday, 30 Jan 2008 | 4:59 PM ET
    GlaxoSmithKline's Avandia

    At 1 pm ET today the embargo was supposed to lift on an article in the scientific journal "Nature" that we got advanced word on early this morning. We were set to post the write-through about it at that time on our web site.

  • Roche Profit Rises on Sales of Cancer Drugs Wednesday, 30 Jan 2008 | 1:10 PM ET

    European pharmaceutical Roche reported a better-than-expected 25 percent increase in fourth-quarter net profit Wednesday on strong sales of its cancer drugs, despite lower sales of its key influenza drug Tamiflu.

  • Merck: Why's Stock So Low? (And What Am I Missing?) Wednesday, 30 Jan 2008 | 12:10 PM ET

    Dow component Merck beat the Street with fourth quarter results on earnings per share (revenue was a sliver below the analyst consensus) and reaffirmed its earnings guidance for this year. Maybe the beaten-down stock is falling victim to another pre-Fed interest rate decision market downdraft...

  • Merck Swings to Loss on Vioxx Charges, Shares Fall Wednesday, 30 Jan 2008 | 10:42 AM ET

    Merck on Wednesday reported a fourth-quarter loss due to charges from a costly settlement related to its withdrawn Vioxx arthritis drug, but results soundly beat Wall Street forecastsand lifted its shares 2 percent.

  • "Dendreonians" were hoping the Provenge controversy might come up for discussion at the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations hearing today.

  • Eli Lilly Prez: EPS Will Soar 'Til 2011 Tuesday, 29 Jan 2008 | 11:50 AM ET

    Eli Lilly posted a higher fourth-quarter profit Tuesday. The pharmaceutical firm cited lower taxes and better-than-expected drug sales -- especially sales of its newer formulations for diabetes and cancer. John Lechleiter, president and chief operating officer -- and Lilly's CEO as of April 1 -- gave CNBC his strong earnings outlook.